1. Canadian Product monograph updates for Keppra, Rifadin

   News item 14 October 2017 Pages: 1 - 1

2. DKMA introduces new practice for follow-up on ADR reports

   News item 14 October 2017 Pages: 2 - 2

3. First high-alert medicine safety self assessment launched

   News item 14 October 2017 Pages: 3 - 3

4. Improved EudraVigilance system due to go live on 22 Nov

   News item 14 October 2017 Pages: 4 - 4

5. PRAC: first public hearing and re-examination request

   News item 14 October 2017 Pages: 5 - 5

6. Kymriah approved despite $475 000 price and toxicities

   News item 14 October 2017 Pages: 6 - 6

7. Gabapentin with opioids: increased opioid-related mortality

   Clinical study 14 October 2017 Pages: 7 - 7

8. Generic vs brand-name angiotensin II receptor blockers

   Clinical study 14 October 2017 Pages: 8 - 8

9. Genotype-guided warfarin dosing prevents more adverse outcomes

   Clinical study 14 October 2017 Pages: 9 - 9

10. Genotyping prior to allopurinol not cost effective

    Clinical study 14 October 2017 Pages: 10 - 10

11. Guillain-Barré syndrome associated with 4HPV vaccine?

    Clinical study 14 October 2017 Pages: 11 - 11

12. Medical events with gabapentin and/or opioid overuse

    Clinical study 14 October 2017 Pages: 12 - 12

13. PADR-EC score may reduce repeat drug-related hospitalisation

    Clinical study 14 October 2017 Pages: 13 - 13

14. Antineoplastics

    Case report 14 October 2017 Pages: 14 - 14

15. Aloe vera/Prunus domestica/interferon-β-1a

    Case report 14 October 2017 Pages: 15 - 15

16. Abatacept/adalimumab/infliximab

    Case report 14 October 2017 Pages: 16 - 16

17. Acenocoumarol

    Case report 14 October 2017 Pages: 17 - 17

18. Acitretin

    Case report 14 October 2017 Pages: 18 - 18

19. Acitretin

    Case report 14 October 2017 Pages: 19 - 19

20. Acitretin/nivolumab

    Case report 14 October 2017 Pages: 20 - 20

21. Aconitum/atropine

    Case report 14 October 2017 Pages: 21 - 21

22. Adalimumab

    Case report 14 October 2017 Pages: 22 - 22

23. Adalimumab

    Case report 14 October 2017 Pages: 23 - 23

24. Adalimumab

    Case report 14 October 2017 Pages: 24 - 24

25. Adalimumab

    Case report 14 October 2017 Pages: 25 - 25

26. Adalimumab

    Case report 14 October 2017 Pages: 26 - 26

27. Adalimumab

    Case report 14 October 2017 Pages: 27 - 27

28. Adalimumab/leflunomide/rituximab

    Case report 14 October 2017 Pages: 28 - 28

29. Adefovir

    Case report 14 October 2017 Pages: 29 - 29

30. Albumin human

    Case report 14 October 2017 Pages: 30 - 30

31. Alemtuzumab

    Case report 14 October 2017 Pages: 31 - 31

32. Alendronic acid

    Case report 14 October 2017 Pages: 32 - 32

33. Alendronic acid

    Case report 14 October 2017 Pages: 33 - 33

34. Alitretinoin

    Case report 14 October 2017 Pages: 34 - 34

35. Allopurinol

    Case report 14 October 2017 Pages: 35 - 35

36. Alteplase

    Case report 14 October 2017 Pages: 36 - 36

37. Alteplase/clopidogrel

    Case report 14 October 2017 Pages: 37 - 37

38. Amikacin/capreomycin

    Case report 14 October 2017 Pages: 38 - 38

39. Aminosalicylic-acid

    Case report 14 October 2017 Pages: 39 - 39

40. Amitriptyline overdose

    Case report 14 October 2017 Pages: 40 - 40

41. Amitriptyline/antihypertensives/doxazosin

    Case report 14 October 2017 Pages: 41 - 41

42. Amoxicillin/clarithromycin/vitamin-k-antagonists interaction

    Case report 14 October 2017 Pages: 42 - 42

43. Amoxicillin/clavulanic-acid

    Case report 14 October 2017 Pages: 43 - 43

44. Ampicillin/sulbactam/clindamycin

    Case report 14 October 2017 Pages: 44 - 44

45. Anastrozole/hydroxychloroquine interaction

    Case report 14 October 2017 Pages: 45 - 45

46. Antibacterials

    Case report 14 October 2017 Pages: 46 - 46

47. Antibacterials

    Case report 14 October 2017 Pages: 47 - 47

48. Antihypertensives

    Case report 14 October 2017 Pages: 48 - 48

49. Antineoplastics

    Case report 14 October 2017 Pages: 49 - 49

50. Antineoplastics

    Case report 14 October 2017 Pages: 50 - 50